{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T10:47:16Z","timestamp":1769942836702,"version":"3.49.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ijcard.2025.134140","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:11:20Z","timestamp":1767917480000},"page":"134140","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["High-intensity versus very-high-intensity statin, both on top of ezetimibe, in acute myocardial infarction: A pragmatic randomized study"],"prefix":"10.1016","volume":"448","author":[{"given":"Simona","family":"Chiusolo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Masini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viola","family":"Zywicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ida Rebecca","family":"Bort","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Malloggi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luna","family":"Gargani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Palagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaele","family":"De Caterina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"38","key":"10.1016\/j.ijcard.2025.134140_bb0005","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur. Heart J."},{"issue":"10","key":"10.1016\/j.ijcard.2025.134140_bb0010","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/j.amjcard.2014.02.034","article-title":"Meta-analysis of time-related benefits of statin therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention","volume":"113","author":"Navarese","year":"2014","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2025.134140_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2024.118540","article-title":"Course of the effects of LDL-cholesterol reduction on cardiovascular risk over time: a meta-analysis of 60 randomized controlled trials","volume":"396","author":"Burger","year":"2024","journal-title":"Atherosclerosis"},{"issue":"32","key":"10.1016\/j.ijcard.2025.134140_bb0020","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur. Heart J."},{"issue":"13","key":"10.1016\/j.ijcard.2025.134140_bb0025","first-page":"e771","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"151","author":"Rao","year":"2025","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ijcard.2025.134140_bb0030","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/eurheartj\/ehaa1011","article-title":"Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: a Swedish nationwide cohort study","volume":"42","author":"Schubert","year":"2021","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.ijcard.2025.134140_bb0035","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"issue":"25","key":"10.1016\/j.ijcard.2025.134140_bb0040","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ijcard.2025.134140_bb0045","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/MCA.0000000000001420","article-title":"Lipid-lowering therapy after acute coronary syndromes: a multinational European survey","volume":"36","author":"Tsaban","year":"2025","journal-title":"Coron. Artery Dis."},{"key":"10.1016\/j.ijcard.2025.134140_bb0050","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejim.2024.02.004","article-title":"Impact of early initiation of ezetimibe in patients with acute coronary syndrome: a systematic review and meta-analysis","volume":"124","author":"Mahajan","year":"2024","journal-title":"Eur. J. Intern. Med."},{"issue":"25","key":"10.1016\/j.ijcard.2025.134140_bb0055","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ijcard.2025.134140_bb0060","doi-asserted-by":"crossref","DOI":"10.57264\/cer-2022-0163","article-title":"Comparative efficacy and safety among high-intensity statins. Systematic review and meta-analysis","volume":"12","author":"Jaam","year":"2023","journal-title":"J. Comp. Eff. Res."},{"issue":"3","key":"10.1016\/j.ijcard.2025.134140_bb0065","first-page":"525","article-title":"Relative safety profiles of high dose statin regimens","volume":"4","author":"Escobar","year":"2008","journal-title":"Vasc. Health Risk Manag."},{"issue":"9753","key":"10.1016\/j.ijcard.2025.134140_bb0070","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2025.134140_bb0075","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.2147\/DDDT.S135173","article-title":"High-dose atorvastatin versus moderate dose on early vascular protection after ST-elevation myocardial infarction","volume":"11","author":"Gavazzoni","year":"2017","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ijcard.2025.134140_bb0080","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-075837","article-title":"Rosuvastatin versus atorvastatin treatment in adults with coronary artery disease: secondary analysis of the randomised LODESTAR trial","volume":"383","author":"Lee","year":"2023","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.ijcard.2025.134140_bb0085","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1001\/jamaophthalmol.2016.5406","article-title":"Association of daily dosage and type of statin agent with risk of open-angle glaucoma","volume":"135","author":"Talwar","year":"2017","journal-title":"JAMA Ophthalmol."},{"issue":"17","key":"10.1016\/j.ijcard.2025.134140_bb0090","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy\u2014European atherosclerosis society consensus panel statement on assessment, aetiology and management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur. Heart J."},{"issue":"3","key":"10.1016\/j.ijcard.2025.134140_bb0095","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/eurheartj\/ehy462","article-title":"Fourth universal definition of myocardial infarction (2018)","volume":"40","author":"Thygesen","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2025.134140_bb0100","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.h391","article-title":"The stepped wedge cluster randomised trial: rationale, design, analysis, and reporting","volume":"350","author":"Hemming","year":"2015","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.ijcard.2025.134140_bb0105","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0002-9149(88)90248-2","article-title":"The Friedewald-Levy-Fredrickson formula for calculating low-density lipoprotein cholesterol, the basis for lipid-lowering therapy","volume":"62","author":"Roberts","year":"1988","journal-title":"Am. J. Cardiol."},{"issue":"2","key":"10.1016\/j.ijcard.2025.134140_bb0110","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10557-020-07137-z","article-title":"LDL cholesterol reduction variability with different types and doses of statins in monotherapy or combined with ezetimibe. Results from the Spanish arteriosclerosis society dyslipidaemia registry","volume":"36","author":"Climent","year":"2022","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"10349","key":"10.1016\/j.ijcard.2025.134140_bb0115","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0140-6736(22)00916-3","article-title":"Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial","volume":"400","author":"Kim","year":"2022","journal-title":"Lancet"},{"issue":"34","key":"10.1016\/j.ijcard.2025.134140_bb0120","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1093\/eurheartj\/ehac015","article-title":"Prevalence of statin intolerance: a meta-analysis","volume":"43","author":"Byty\u00e7i","year":"2022","journal-title":"Eur. Heart J."},{"issue":"2","key":"10.1016\/j.ijcard.2025.134140_bb0125","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1161\/ATV.0000000000000073","article-title":"Statin safety and associated adverse events: a scientific statement from the American Heart Association","volume":"39","author":"Newman","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"6","key":"10.1016\/j.ijcard.2025.134140_bb0130","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1592\/phco.30.6.541","article-title":"Statin-associated muscle-related adverse effects: a case series of 354 patients","volume":"30","author":"Cham","year":"2010","journal-title":"Pharmacotherapy"},{"issue":"4","key":"10.1016\/j.ijcard.2025.134140_bb0135","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1161\/CIRCOUTCOMES.111.000071","article-title":"Comparative tolerability and harms of individual statins","volume":"6","author":"Naci","year":"2013","journal-title":"Circ. Cardiovasc. Qual. Outcomes."},{"issue":"9","key":"10.1016\/j.ijcard.2025.134140_bb0140","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.118.002228","article-title":"Effects of delivering <i>SLCO1B1<\/i> pharmacogenetic information in randomized trial and observational settings","volume":"11","author":"Peyser","year":"2018","journal-title":"Circ. Genom. Precis. Med."},{"issue":"12","key":"10.1016\/j.ijcard.2025.134140_bb0145","first-page":"939","volume":"11","author":"Krychtiuk","year":"2022","journal-title":"Eur. Heart J. Acute Cardiovasc. Care"},{"issue":"12","key":"10.1016\/j.ijcard.2025.134140_bb0150","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1093\/cvr\/cvae109","article-title":"Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial","volume":"120","author":"Wright","year":"2024","journal-title":"Cardiovasc. Res."},{"issue":"15","key":"10.1016\/j.ijcard.2025.134140_bb0155","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13154543","article-title":"Monoclonal anti-PCSK9 antibodies: real-world data","volume":"13","author":"Guidotti","year":"2024","journal-title":"J. Clin. Med."},{"issue":"18","key":"10.1016\/j.ijcard.2025.134140_bb0160","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.ijcard.2025.134140_bb0165","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ijcard.2025.134140_bb0170","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias: developed by the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2025","journal-title":"Eur. Heart J."},{"issue":"3","key":"10.1016\/j.ijcard.2025.134140_bb0175","doi-asserted-by":"crossref","first-page":"165","DOI":"10.5603\/DK.a2022.0021","article-title":"Efficacy and safety of atorvastatin 40 mg versus rosuvastatin 20 mg in patients with Type 2 diabetes mellitus and previous acute coronary syndrome: a randomized clinical trial","volume":"11","author":"Ebid","year":"2022","journal-title":"Clin. Diabetol."},{"issue":"16","key":"10.1016\/j.ijcard.2025.134140_bb0180","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.019270","article-title":"Characteristics and outcomes of early recurrent myocardial infarction after acute myocardial infarction","volume":"10","author":"Nair","year":"2021","journal-title":"J. Am. Heart Assoc."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527325011830?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527325011830?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T20:47:19Z","timestamp":1769892439000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527325011830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":36,"alternative-id":["S0167527325011830"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2025.134140","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-intensity versus very-high-intensity statin, both on top of ezetimibe, in acute myocardial infarction: A pragmatic randomized study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2025.134140","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"134140"}}